Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: A meta-analysis of randomized phase III trials

Journal of Clinical Oncology

Volumn 35, Issue 6, 2017, Pages 622-628

  Jackson, Richard ^a   Psarelli, Eftychia Eirini ^a   Berhane, Sarah ^a   Khan, Harun ^b   Johnson, Philip ^a,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; LINIFANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; BAYES THEOREM; CANCER PATIENT; CANCER SURVIVAL; HAZARD RATIO; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85013293335     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.5197     Document Type: Article

References (32)

1. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 379:1245-1255, 2012
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
3. Bruix J, Sherman M: Management of hepatocellular carcinoma: An update. Hepatology 53:1020-1022, 2011
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
6. Bruix J, Raoul JL, Sherman M, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57:821-829, 2012
7. Cabrera R, Limaye AR, Horne P, et al: The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther 37:91-97, 2013
8. Johnson PJ, Qin S, Park JW, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517-3524, 2013
9. Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 31:4067-4075, 2013
10. Cainap C, Qin S, Huang WT, et al: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015
11. Shao YY, Shau WY, Chan SY, et al: Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials. Oncology 88:345-352, 2015
12. Kelley RK, Venook AP: Sorafenib in hepatocellular carcinoma: Separating the hype from the hope. J Clin Oncol 26:5845-5848, 2008
13. Harding JJ, Abou-Alfa GK: Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer 120:3122-3130, 2014
14. Huitzil FD, Saltz LS, Song J, et al: Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S. ), In ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, USA, 2007.
15. Riley RD, Lambert PC, Abo-Zaid G: Meta-analysis of individual participant data: Rationale, conduct, and reporting. BMJ 340:c221, 2010
16. Riley RD, Lambert PC, Staessen JA, et al: Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med 27:1870-1893, 2008
17. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
18. Gelman A, Carlin JB, Stern HS, et al: Bayesian data analysis. Boca Raton, FL, Chapman & Hall/CRC, 2014.
19. Friedman M.: Piecewise exponential models for survival data with covariates. Ann Stat 10:101-113, 1982
20. Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
21. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339:b2535, 2009
22. Boyault S, Rickman DS, de Reyniès A, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52, 2007
23. Guichard C, Amaddeo G, Imbeaud S, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698, 2012
24. Lachenmayer A, Alsinet C, Savic R, et al: Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18:4997-5007, 2012
25. Villanueva A, Toffanin S, Llovet JM: Linking molecular classification of hepatocellular carcinoma and personalized medicine: Preliminary steps. Curr Opin Oncol 20:444-453, 2008
26. Fujimoto A, Totoki Y, Abe T, et al: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44:760-764, 2012
27. Himmelsbach K, Sauter D, Baumert TF, et al: New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replication. Gut 58:1644-1653, 2009
28. Tornesello ML, Buonaguro L, Tatangelo F, et al: Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 102:74-83, 2013
29. Giambartolomei S, Covone F, Levrero M, et al: Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20:2606-2610, 2001
30. Braconi C, Valeri N, Gasparini P, et al: : Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res 16:957-966, 2010
31. Bruix J, Takayama T, Mazzaferro V, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16:1344-1354, 2015
32. Taichman DB, Backus J, Baethge C, et al: Sharing clinical trial data: A proposal from the International Committee of Medical Journal Editors. JAMA 315:467-468, 2016